Treatment
Table 1. Reasonable dose/schedule details for recommended
regimens – Adjuvant Therapy
Regimen
(Recommendation #) Dosing Schedules (Source)
Pembrolizumab × 52 weeks
(2.2, 2.3, 2.6)
Pembrolizumab 200 mg/kg every 3 weeks by intravenous
infusion for 52 weeks (EORTC 1325)
Nivolumab × 52 weeks
(2.2, 2.3, 2.5)
Nivolumab 240 mg every 2 weeks or 480 mg every 4
weeks by intravenous infusion for 52 weeks (Checkmate
238 and US FDA label)
Dabrafenib plus trametinib ×
52 weeks (2.3, 2.6)
Dabrafenib 150 mg orally twice daily plus trametinib
2 mg orally once daily for 52 weeks (COMBI-AD)
